{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:21:08Z","timestamp":1792423268797,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"am","delay-in-days":280,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neuropharm.2025.110334","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T02:19:47Z","timestamp":1738376387000},"page":"110334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice"],"prefix":"10.1016","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2605-1338","authenticated-orcid":false,"given":"Michael","family":"Noback","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny A.","family":"Kenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-8755","authenticated-orcid":false,"given":"Andrew C.","family":"Kruegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3618-584X","authenticated-orcid":false,"given":"Yasmin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Halberstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-5776","authenticated-orcid":false,"given":"Jared W.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.neuropharm.2025.110334_bib1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1021\/jm00256a016","article-title":"Structure-activity relationships in psychotomimetic phenylalkylamines","volume":"17","author":"Aldous","year":"1974","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-017-4773-8","article-title":"High and escalating levels of cocaine intake are dissociable from subsequent incentive motivation for the drug in rats","volume":"235","author":"Allain","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41398-024-02900-4","article-title":"LSD increases sleep duration the night after microdosing","volume":"14","author":"Allen","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0306-4522(91)90128-B","article-title":"5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex","volume":"40","author":"Araneda","year":"1991","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/schbul\/sbp139","article-title":"Anticipating DSM-V: opportunities and challenges for cognition and psychosis","volume":"36","author":"Barch","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110334_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00213-003-1751-0","article-title":"Free operant and discrete trial performance of mice in the nine-hole box apparatus: validation using amphetamine and scopolamine","volume":"174","author":"Bensadoun","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110334_bib7","first-page":"461","article-title":"Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity","volume":"5","author":"Bershad","year":"2020","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimag."},{"key":"10.1016\/j.neuropharm.2025.110334_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.schres.2017.06.042","article-title":"Relationship between effortful motivation and neurocognition in schizophrenia","volume":"193","author":"Bismark","year":"2018","journal-title":"Schizophr. Res."},{"issue":"24","key":"10.1016\/j.neuropharm.2025.110334_bib9","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm000339w","article-title":"Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines","volume":"43","author":"Blair","year":"2000","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/dta.2222","article-title":"Return of the lysergamides. Part IV: analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)","volume":"10","author":"Brandt","year":"2018","journal-title":"Drug Test Anal."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10899-013-9430-5","article-title":"Inpatient treatment for pathological gamblers in Germany: setting, utilization, and structure","volume":"31","author":"Buchner","year":"2015","journal-title":"J. Gambl. Stud."},{"issue":"7842","key":"10.1016\/j.neuropharm.2025.110334_bib12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.neuropharm.2025.110334_bib13","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110334_bib14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/schbul\/sbm081","article-title":"Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative","volume":"33","author":"Carter","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41398-021-01562-w","article-title":"Electrophysiological biomarkers of behavioral dimensions from cross-species paradigms","volume":"11","author":"Cavanagh","year":"2021","journal-title":"Transl. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110334_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1503\/jpn.120181","article-title":"Dopamine and light: dissecting effects on mood and motivational states in women with subsyndromal seasonal affective disorder","volume":"38","author":"Cawley","year":"2013","journal-title":"J. Psychiatry Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110334_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3758\/s13415-020-00824-2","article-title":"Converging evidence that short-active photoperiod increases acetylcholine signaling in the hippocampus","volume":"20","author":"Cope","year":"2020","journal-title":"Cogn. Affect Behav. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acschemneuro.2c00597","article-title":"Pharmacological mechanism of the non-hallucinogenic 5-HT(2A) agonist ariadne and analogs","volume":"14","author":"Cunningham","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/wps.20087","article-title":"The RDoC framework: facilitating transition from ICD\/DSM to dimensional approaches that integrate neuroscience and psychopathology","volume":"13","author":"Cuthbert","year":"2014","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110334_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110334_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib22","first-page":"12","article-title":"Best practices for using median splits, artificial categorization, and their continuous alternatives","volume":"2","author":"DeCoster","year":"2011","journal-title":"J. Exp. Psychopathol."},{"key":"10.1016\/j.neuropharm.2025.110334_bib23","article-title":"Cross-species translational paradigms for assessing positive valence system as defined by the RDoC matrix","author":"Dexter","year":"2024","journal-title":"J. Neurochem"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41398-019-0674-4","article-title":"Chronic corticosterone administration induces negative valence and impairs positive valence behaviors in mice","volume":"9","author":"Dieterich","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110334_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1017\/neu.2018.14","article-title":"Individual responses of rodents in modelling of affective disorders and in their treatment: prospective review","volume":"30","author":"Einat","year":"2018","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.neuropharm.2025.110334_bib26","series-title":"The Psychedelic Explorer\u2019s Guide : Safe, Therapeutic, and Sacred Journeys","author":"Fadiman","year":"2011"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110334_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/jpet.110.172247","article-title":"Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice","volume":"335","author":"Fantegrossi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2025.110334_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.psc.2023.02.003","article-title":"Pharmacotherapy: ketamine and esketamine","author":"Feeney","year":"2023","journal-title":"Psychiatry Clin. N. Am."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110334_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/105504900750047355","article-title":"What we have learned about addiction from animal models of drug self-administration","volume":"9","author":"Gardner","year":"2000","journal-title":"Am. J. Addict."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41386-022-01479-y","article-title":"Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity","volume":"48","author":"Glazer","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110334_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0091-3057(82)90414-2","article-title":"A comparison of the behavioral effects of DOM homologs","volume":"16","author":"Glennon","year":"1982","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"25","key":"10.1016\/j.neuropharm.2025.110334_bib32","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","article-title":"Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents","volume":"35","author":"Glennon","year":"1984","journal-title":"Life Sci."},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110334_bib33","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1021\/jm00039a004","article-title":"Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines","volume":"37","author":"Glennon","year":"1994","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110334_bib34","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/nprot.2011.361","article-title":"A standardized protocol for repeated social defeat stress in mice","volume":"6","author":"Golden","year":"2011","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110334_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonzalez-Maeso","year":"2007","journal-title":"Neuron"},{"issue":"18","key":"10.1016\/j.neuropharm.2025.110334_bib36","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110334_bib37","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110334_bib38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.neuron.2019.05.042","article-title":"Orbitofrontal circuits control multiple reinforcement-learning processes","volume":"103","author":"Groman","year":"2019","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110334_bib39","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s00213-018-4969-6","article-title":"Validation and optimisation of a touchscreen progressive ratio test of motivation in male rats","volume":"235","author":"Hailwood","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib40","doi-asserted-by":"crossref","first-page":"8344","DOI":"10.1038\/s41598-020-65264-x","article-title":"Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network","volume":"10","author":"Halberstadt","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110334_bib41","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/npp.2009.29","article-title":"5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice","volume":"34","author":"Halberstadt","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110334_bib42","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1177\/0269881110388326","article-title":"Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice","volume":"25","author":"Halberstadt","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110334_bib43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuropharm.2013.01.014","article-title":"Role of the 5-HT(2)A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice","volume":"70","author":"Halberstadt","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110334_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"issue":"21\u201322","key":"10.1016\/j.neuropharm.2025.110334_bib45","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1007\/s00213-015-4009-8","article-title":"Motivational assessment of mice using the touchscreen operant testing system: effects of dopaminergic drugs","volume":"232","author":"Heath","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110334_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jad.2016.02.003","article-title":"Diminished effort on a progressive ratio task in both unipolar and bipolar depression","volume":"196","author":"Hershenberg","year":"2016","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.neuropharm.2025.110334_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.640241","article-title":"Low doses of psilocybin and ketamine enhance motivation and attention in poor performing rats: evidence for an antidepressant property","volume":"12","author":"Higgins","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3483","key":"10.1016\/j.neuropharm.2025.110334_bib48","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.134.3483.943","article-title":"Progressive ratio as a measure of reward strength","volume":"134","author":"Hodos","year":"1961","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110334_bib49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1901\/jeab.1963.6-387","article-title":"Effects of increment size and reinforcer volume on progressive ratio performance","volume":"6","author":"Hodos","year":"1963","journal-title":"J. Exp. Anal. Behav."},{"key":"10.1016\/j.neuropharm.2025.110334_bib50","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fpsyt.2019.00672","article-title":"Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers","volume":"10","author":"Hutten","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110334_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","article-title":"Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study","volume":"41","author":"Hutten","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110334_bib52","first-page":"14","article-title":"Toward a more nuanced understanding of the statistical properties of a median split","volume":"25","author":"Iacobucci","year":"2014","journal-title":"J. Consum. Psychol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110334_bib53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jcps.2015.06.014","article-title":"The median split: robust, refined, and revived","volume":"25","author":"Iacobucci","year":"2015","journal-title":"J. Consum. Psychol."},{"issue":"502","key":"10.1016\/j.neuropharm.2025.110334_bib54","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/01621459.2013.770702","article-title":"Bayesian hierarchical Poisson regression models: an application to a driving study with kinematic events","volume":"108","author":"Kim","year":"2013","journal-title":"J. Am. Stat. Assoc."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0193-953X(05)70272-0","article-title":"Symptomatology in dysthymic and major depressive disorder","volume":"19","author":"Klein","year":"1996","journal-title":"Psychiatry Clin. North Am."},{"key":"10.1016\/j.neuropharm.2025.110334_bib56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neuropharm.2018.02.028","article-title":"Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs","volume":"142","author":"Klein","year":"2018","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acsptsci.0c00176","article-title":"Investigation of the structure-activity relationships of psilocybin analogues","volume":"4","author":"Klein","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2025.110334_bib58","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejphar.2008.06.063","article-title":"Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy","volume":"591","author":"Knauer","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110334_bib59","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/jnnp-2018-318265","article-title":"Brain mechanisms underlying apathy","volume":"90","author":"Le Heron","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110334_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.11.008","article-title":"Microdosing psychedelics: motivations, subjective effects and harm reduction","volume":"75","author":"Lea","year":"2020","journal-title":"Int. J. Drug Policy"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110334_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112203","article-title":"A non-hallucinogenic LSD analog with therapeutic potential for mood disorders","volume":"42","author":"Lewis","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib62","article-title":"Modern psychedelic microdosing research on mental health: a systematic review","volume":"26","author":"Lo","year":"2024","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110334_bib63","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib64","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/acsptsci.0c00065","article-title":"Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth","volume":"4","author":"Ly","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib65","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0026-895X(25)10354-4","article-title":"3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors","volume":"31","author":"Lyon","year":"1987","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110334_bib66","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2025.110334_bib67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02244907","article-title":"Animal models of drug craving","volume":"112","author":"Markou","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110334_bib68","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac278","article-title":"Different depression: motivational anhedonia governs antidepressant efficacy in Huntington\u2019s disease","volume":"4","author":"McLauchlan","year":"2022","journal-title":"Brain Commun."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110334_bib69","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1177\/0269881117731162","article-title":"Blockade of dopamine D(1)-family receptors attenuates the mania-like hyperactive, risk-preferring, and high motivation behavioral profile of mice with low dopamine transporter levels","volume":"31","author":"Milienne-Petiot","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110334_bib70","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.euroneuro.2018.08.005","article-title":"Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning","volume":"28","author":"Milienne-Petiot","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110334_bib71","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41386-023-01772-4","article-title":"Greater subjective effects of a low dose of LSD in participants with depressed mood","volume":"49","author":"Molla","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12868-024-00844-5","article-title":"Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial","volume":"25","author":"Murphy","year":"2024","journal-title":"BMC Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110334_bib73","first-page":"500","article-title":"Microdosing psychedelics: current evidence from controlled studies","volume":"9","author":"Murphy","year":"2024","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimag."},{"issue":"7754","key":"10.1016\/j.neuropharm.2025.110334_bib74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-019-1075-9","article-title":"Oxytocin-dependent reopening of a social reward learning critical period with MDMA","volume":"569","author":"Nardou","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00005315","article-title":"Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors","volume":"359","author":"Nelson","year":"1999","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110334_bib76","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/cn500292d","article-title":"N-Benzyl-5-methoxytryptamines as potent serotonin 5-HT2 receptor family agonists and comparison with a series of phenethylamine analogues","volume":"6","author":"Nichols","year":"2015","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib77","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3758\/s13415-023-01150-z","article-title":"Amphetamine increases motivation of humans and mice as measured by breakpoint, but does not affect an Electroencephalographic biomarker","volume":"24","author":"Noback","year":"2024","journal-title":"Cogn. Affect Behav. Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110334_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.208","article-title":"Models of depression: unpredictable chronic mild stress in mice","volume":"1","author":"Nollet","year":"2021","journal-title":"Curr. Protoc."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110334_bib79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/acs.biochem.1c00812","article-title":"Biochemical mechanisms underlying psychedelic-induced neuroplasticity","volume":"61","author":"Olson","year":"2022","journal-title":"Biochemistry"},{"issue":"33","key":"10.1016\/j.neuropharm.2025.110334_bib80","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021497","article-title":"Selective serotonin reuptake inhibitors-associated apathy syndrome: a cross sectional study","volume":"99","author":"Padala","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2025.110334_bib81","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.schres.2014.11.005","article-title":"Altered cingulo-striatal function underlies reward drive deficits in schizophrenia","volume":"161","author":"Park","year":"2015","journal-title":"Schizophr Res."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110334_bib82","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/npp.2017.52","article-title":"5-HT(2C) agonists modulate schizophrenia-like behaviors in mice","volume":"42","author":"Pogorelov","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110334_bib83","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/02698811241254831","article-title":"Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research","volume":"38","author":"Polito","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110334_bib84","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1073\/pnas.1815129116","article-title":"Effective connectivity changes in LSD-induced altered states of consciousness in humans","volume":"116","author":"Preller","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110334_bib85","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41380-019-0615-x","article-title":"Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model","volume":"25","author":"Price","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib86","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1038\/s41598-019-40532-7","article-title":"Prelimbic and infralimbic cortical inactivations attenuate contextually driven discriminative responding for reward","volume":"9","author":"Riaz","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110334_bib87","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01811-4","article-title":"Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers","volume":"11","author":"Rootman","year":"2021","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110334_bib89","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110334_bib90","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrn3381","article-title":"The brain reward circuitry in mood disorders","volume":"14","author":"Russo","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110334_bib91","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212290","article-title":"Antidepressant efficacy and side-effect burden: a quick guide for clinicians","author":"Santarsieri","year":"2015","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)09485-6","article-title":"(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A\/2C antagonists, D1 antagonists and 5-HT1A agonists","volume":"273","author":"Schreiber","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2025.110334_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2022.1020146","article-title":"5-HT(1B) receptor agonist enhances breakpoint for cocaine on a progressive ratio (PR) schedule during maintenance of self-administration in female rats but reduces breakpoint for sucrose","volume":"16","author":"Scott","year":"2022","journal-title":"Front. Behav. Neurosci."},{"issue":"16","key":"10.1016\/j.neuropharm.2025.110334_bib94","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2025.110334_bib95","series-title":"4-Alkyl-dialkoxy-\u03b1-methyl-phenethylamines and Their Pharmacologically-Acceptable Salts","author":"Shulgin","year":"1970"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110334_bib96","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1021\/jm00246a006","article-title":"Psychotomimetic phenylisopropylamines. 5. 4-Alkyl-2,5-dimethoxyphenylisopropylamines","volume":"18","author":"Shulgin","year":"1975","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110334_bib97","series-title":"Pihkal : a Chemical Love Story","author":"Shulgin","year":"1991"},{"key":"10.1016\/j.neuropharm.2025.110334_bib98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpsychires.2021.05.019","article-title":"Registered clinical studies investigating psychedelic drugs for psychiatric disorders","volume":"139","author":"Siegel","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-2952(95)02122-1","article-title":"Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities","volume":"51","author":"Sleight","year":"1996","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110334_bib100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.physbeh.2017.04.016","article-title":"Modeling hypohedonia following repeated social defeat: individual vulnerability and dopaminergic involvement","volume":"177","author":"Spierling","year":"2017","journal-title":"Physiol. Behav."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110334_bib101","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881120959609","article-title":"Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans","volume":"35","author":"Stenbaek","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib102","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2015.12.006","article-title":"Avolition in schizophrenia is associated with reduced willingness to expend effort for reward on a Progressive Ratio task","volume":"170","author":"Strauss","year":"2016","journal-title":"Schizophr Res."},{"issue":"19","key":"10.1016\/j.neuropharm.2025.110334_bib103","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/0006-2952(87)90643-5","article-title":"Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand","volume":"36","author":"Titeler","year":"1987","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib104","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","article-title":"Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens","volume":"94","author":"Titeler","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110334_bib105","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.euroneuro.2014.04.008","article-title":"Pay attention to impulsivity: modelling low attentive and high impulsive subtypes of adult ADHD in the 5-choice continuous performance task (5C-CPT) in female rats","volume":"24","author":"Tomlinson","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib106","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\u2217D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110334_bib107","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1038\/npp.2014.170","article-title":"Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder","volume":"39","author":"van Enkhuizen","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"17","key":"10.1016\/j.neuropharm.2025.110334_bib108","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib109","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT(2A) receptor signaling pathways associated with psychedelic potential","volume":"14","author":"Wallach","year":"2023","journal-title":"Nat. Commun."},{"issue":"502","key":"10.1016\/j.neuropharm.2025.110334_bib110","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/01621459.2013.775949","article-title":"Auxiliary marker-assisted classification in the absence of class identifiers","volume":"108","author":"Wang","year":"2013","journal-title":"J. Am. Stat. Assoc."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110334_bib111","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11731","article-title":"Acute and longer-term outcomes using ketamine as a clinical treatment at the yale psychiatric hospital","volume":"79","author":"Wilkinson","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110334_bib112","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/schbul\/sbu026","article-title":"Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures","volume":"40","author":"Wolf","year":"2014","journal-title":"Schizophr Bull."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110334_bib113","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110334_bib114","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.neubiorev.2013.07.002","article-title":"Rats classified as low or high cocaine locomotor responders: a unique model involving striatal dopamine transporters that predicts cocaine addiction-like behaviors","volume":"37","author":"Yamamoto","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2025.110334_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105119","article-title":"Development of cross-species translational paradigms for psychiatric research in the Research Domain Criteria era","volume":"148","author":"Young","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110334_bib116","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.biopsych.2009.12.015","article-title":"Action of modafinil--increased motivation via the dopamine transporter inhibition and D1 receptors?","volume":"67","author":"Young","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110334_bib117","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/schbul\/sbv093","article-title":"Translational rodent paradigms to investigate neuromechanisms underlying behaviors relevant to amotivation and altered reward processing in schizophrenia","volume":"41","author":"Young","year":"2015","journal-title":"Schizophr Bull."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110334_bib118","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1601-183X.2011.00711.x","article-title":"Delayed procedural learning in alpha7-nicotinic acetylcholine receptor knockout mice","volume":"10","author":"Young","year":"2011","journal-title":"Genes Brain Behav."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110334_bib119","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bdi.12786","article-title":"Convergent neural substrates of inattention in bipolar disorder patients and dopamine transporter-deficient mice using the 5-choice CPT","volume":"22","author":"Young","year":"2020","journal-title":"Bipolar Disord."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2025.110334_bib120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejphar.2007.12.005","article-title":"A mouse model of depression induced by repeated corticosterone injections","volume":"581","author":"Zhao","year":"2008","journal-title":"Eur. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:35:36Z","timestamp":1778733336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":120,"alternative-id":["S0028390825000401"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110334","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110334"}}